Role of Ayurveda-based Diet and Panchakarma Therapy on Quantitative Change in Coronary Atherosclerosis in Known CAD Assessed by Quantitative CT Coronary Angiography
Issue: 2023 - Volume 6 [Issue 1]
Rupali Kaware *
Rajapeth Clinic, Amravati, Maharashtra, India.
Madhavbaug Cardiac Clinic and Hospital, Thane, Maharashtra, India.
*Author to whom correspondence should be addressed.
Background: Ischemic heart disease (IHD), a form of coronary artery disease(CAD), is one of the many cardiovascular diseases (CVDs) whose prevalence has reached epidemic proportions. The initial symptom of coronary artery disease is the development of atherosclerotic plaques in the coronary arteries. The greatest pharmaceutical strategy to manage atherosclerosis, however, still does not seem to appear to have widespread acceptance.
Aim: To study the effect of restricted diet and Ischemia Reversal Program(IRP) panchakarma therapy on quantitative change in coronary atherosclerosis in known CAD assessed by quantitative CT coronary angiography.
Methods: A total of 17 patients suffering from CAD were administrated IRP and restricted diet program for 90 days with regular follow-ups. Basic demographics, stress test, 2D echo, and computerized tomography (CT) coronary angiography test for all the patients were recorded before and after the treatment.
Results: It was observed that 26.80% regression in Total atheroma volume(TAV), followed by 30.19% regression in high-density plaque, and 25.82% regression in low-density plaque was found in patients after the treatment. The total atheroma value is reduced by 160.7 mm (p<0.00). The baseline average weight of the patient decreased from 68.28 Kg to 63.97 Kg (p<0.02).
Conclusion: IRP can help to stabilize the plaque for a longer lifespan in addition to decreasing the development of atherosclerosis when combined with a limited diet. The results of our study indicate that IRP Panchakarma therapy, in conjunction with restricted diet programs, can be used to treat individuals with coronary atherosclerosis who have known coronary artery disease as measured by quantitative CT angiography.
Keywords: Coronary artery disease, atherosclerotic plaque, ischemia reversal program
How to Cite
Fuster V, Kelly B. Board for global health. Promoting cardiovascular health in developing world: a critical challenge to achieve global health. Washington, DC: Institutes of Medicine; 2010.
Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low-and middle-income countries. Current problems in cardiology. 2010;35(2):72-115.
Gaziano T, Gaziano J. Epidemiology of cardiovascular disease. In: Harrison’s Principles of internal medicine. 19th ed. New York, NY: McGraw Hill. 2016:266.e1e5.
Zhou JI, Chew M, Ravn HB, Falk E. Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes. Scandinavian Journal of Clinical and Laboratory Investigation. 1999;59(sup230):3-11.
Fuster V, Badimon L, Badimon J, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med.1992;326:242-250,310-318.
Neiderud CJ. How urbanization affects the epidemiology of emerging infectious diseases. Infection ecology & epidemiology. 2015;5(1):27060.
Lam D, Nadkarni GN, Mosoyan G, Neal B, Mahaffey KW, Rosenthal N, Hansen MK, Heerspink HJ, Fleming F, Coca SG. Clinical utility of KidneyIntelX in early stages of diabetic kidney disease in the CANVAS trial. American Journal of Nephrology. 2022;53(1):21-31.
Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am CollCardiol 1988;12:56-62.
Ramesh S, Kosalram K. The burden of non‑communicable diseases: A scoping review focus on the context of India. Journal of Education and Health Promotion. 2023;13(2):1-7.
Smith P. Antithrombotic therapy in the chronic phase myocardial infarction. In: Fuster V, Verstraete M (eds). Thrombosis in Cardiovascular Disorder. W. B. Saunders Philadelphia, PA. 1992;343–62.
Lip GY, Barnett AH, Bradbury A, Cappuccio FP, Gill PS, Hughes E, Imray C, Jolly K, Patel K. Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. Journal of human hypertension. 2007;21(3):183-211.
Eraballi A, Pradhan B. Quality of life improvement with rehabilitation according to constitution of the World Health Organization for coronary artery bypass graft surgery patients: A descriptive review. Ayu. 2017;38(3-4):102.
Tabish SA. Complementary and alternative healthcare: is it evidence-based?. International journal of health sciences. 2008;2(1):V.
Pawar P, Pawar D, Anjankar S. Role of Low Carbohydrate Diet and Panchakarma Therapy in Reduction of Hba1c with Special Reference to Diabetic Retinopathy in Type 2 Diabetes Mellitus-Case Series. Science. 2023;8(1):5-9.
Ghadigaonkar P, Amin G, Mandole R, Sane R. Impact of Panchakarma Therapy and Diet Modification on Lipid Level on known Dyslipidemia Patients. Journal of Advances in Medicine and Medical Research. 2021;33(9):71-7.
Sane R, Mandole R, Amin G, Ghadigaonkar P, Dawkhar S. Effect of herbal detoxification and reverse diet treatment on the mortality rate of CAD patients.
Sane R, Aklujkar A, Patil A, Mandole R. Effect of heart failure reversal treatment as add-on therapy in patients with chronic heart failure: A randomized, open-label study. Indian Heart Journal. 2017;69(3): 299-304.
Staesssen J, Fagard R, Amery A. The relationship between body weight and blood pressure. J Hum Hypertens, 1988;2(4):207.
Sane R, Sugwekar V, Nadapude A, Hande A, Depe G, Mandole R. Study of efficacy of ischemia reversal program (IRP) in ischemic heart disease (IHD) patients with VO2max and Duke’s treadmill score. Int J Basic Clin Pharmacol. 2018;7: 1642-7.
Choudhary K, Sharma P, Sharma V. Hypertension and its management through Panchakarma, J of Ayurveda and Hol Med. 2015;3(3):28-31.
Zhang S, Li H, Yang S. Tribulosin protects rat hearts from ischemia/reperfusion injury. Acta Pharmacologica Sinica. 2010;31(6): 671-78. 23.
Bhattacharjee S, Banerjee N, Chatterjee S, Santra T, Chatterjee S, Chatterjee A, et al. Role of turmeric in management of different non-communicable diseases. World J Pharm Pharm Sci. 2017;6: 1767-78.
Gopa B, Bhatt J, Hemavathi K. A comparative clinical study of hypolipidemic efficacy of Amla (Emblica officinalis) with 3-hydroxy-3-methylglutarylcoenzyme-A reductase inhibitor simvastatin. Indian J Pharmacology. 2012;44(2):238-42.
Chhatre S, Nesari T, Somani G, Kanchan D, Sathaye S. Phytopharmacological overview of Tribulus terrestris. Pharmacognosy Reviews. 2014;8 (15):45
Sane R, Mandole R, Amin G. Use of reverse diet kit as a treatment to regress atheroma in a known CAD patient: A case report. J Ayurveda Integr Med. 2022;13(2): 100511.